N/A N=111 iCanCope With Sickle Cell Pain
Sickle Cell Disease
Primary: Pain Diary - Average Daily Pain — 2.7; 3.3; 2.6; 3.3 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=208 Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety
Erosive Esophagitis
Primary: Number of Participants With Malignant Alteration of Epithelial Cells — 0; 0 Participants
Phase 3 N=32 A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Congenital Hyperinsulinism
Primary: Hypoglycemia Episode Rate — 5.29; 5.85; -3.05; -3.15 episodes per week — p=0.5028
Phase 2 N=54 Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics
Alcohol Use Disorder · Bipolar Disorder
Primary: Prefrontal GABA+ Concentrations — 3.90; 3.93; 3.73 mmol/kg
Phase 4 N=81 A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections
Hypogonadism, Male
Primary: Change in Hematocrit (Hct) Levels. — 3.0; -0.6 percentage of hematocrit
N/A N=26 Feasibility and Preliminary Effects of MR-005 in Persons With Parkinson Disease
Parkinson Disease
Primary: Observed Adherence (Feasibility) to Walking Program Schedule Based on Percentage of Scheduled Sessions Completed — 86.08696 percent of sessions completed
N/A N=115 Opioid Treatment and Recovery Through a Safe Pain Management Program
Depression · Opioid Use · Chronic Pain
Primary: Odds of Morphine Equivalent Daily Dose (MEDD) of Opioid Prescription >=50 mg — 0.209; 0.417; 0.185; 0.364 odds of prescription high dose — p=0.956
Phase 3 N=252 A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
Schizophrenia · Schizophrenia; Psychosis
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 — -21.2; -11.6 score on a scale — p=<0.0001
Phase 2 N=31 Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Number of Subjects With Major Pathologic Response (MPR) — 17 Participants
N/A N=280 Prospective RCT Of Water Exchange (WE) vs. WE Plus Cap-Assisted Colonoscopy
Unsedated Colonoscopy · Water Exchange Colonoscopy · Cap
Primary: Real Time Maximum Insertion Pain — 2.6; 2.9 score on a scale — p=0.62
N/A N=79 ASPIRE Cognitive Enhancement Study
Homelessness · Mental Health Conditions
Primary: Change in Global Deficit Score From Expanded MATRICS Consensus Cognitive Battery (MCCB) — 0.26; .14 score on a scale
Phase 2 N=100 Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Breast Cancer
Primary: Invasive Disease-free Survival (DFS) — 42; 47 Participants
Phase 2 N=80 Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants
Helicobacter Pylori Infection
Primary: The Eradication Rate of Helicobacter Pylori Infection — 18; 17; 5; 10 Participants
Phase 2 N=214 A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Colitis, Ulcerative
Primary: Combination Phase: Percentage of Participants Who Achieved Clinical Response at Week 12 — 61.1; 74.6; 83.1 Percentage of participants
Phase 3 N=1,250 A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Breast Cancer · Hormonreceptor Positive · Her2-normal
Primary: Invasive Disease Free Survival (iDFS) for Palbociclib vs. Placebo in Patients With High CPS-EG Score After Neoadjuvant Chemotherapy Receiving Standard Adjuvant Endocrine…